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Abstract: Background: Heparin and heparin-related sulphated carbohydrates inhibit ligand binding
of the receptor for advanced glycation end products (RAGE). Here, we have studied the ability
of heparin to inhibit homophilic interactions of RAGE in living cells and studied how heparin
related structures interfere with RAGE–ligand interactions. Methods: Homophilic interactions of
RAGE were studied with bead aggregation and living cell protein-fragment complementation assays.
Ligand binding was analyzed with microwell binding and chromatographic assays. Cell surface
advanced glycation end product binding to RAGE was studied using PC3 cell adhesion assay.
Results: Homophilic binding of RAGE was mediated by V1- and modulated by C2-domain in
bead aggregation assay. Dimerisation of RAGE on the living cell surface was inhibited by heparin.
Sulphated K5 carbohydrate fragments inhibited RAGE binding to amyloid β-peptide and HMGB1.
The inhibition was dependent on the level of sulfation and the length of the carbohydrate backbone.
α-D-Glucopyranosiduronic acid (glycyrrhizin) inhibited RAGE binding to advanced glycation end
products in PC3 cell adhesion and protein binding assays. Further, glycyrrhizin inhibited HMGB1
and HMGB1 A-box binding to heparin. Conclusions: Our results show that K5 polysaccharides and
glycyrrhizin are promising candidates for RAGE targeting drug development.
Keywords: dimerization; glycyrrhizin; heparin; HMGB1; K5; RAGE
1. Introduction
The receptor for advanced glycation end products (RAGE) is a multiligand cell surface
transmembrane receptor that regulates normal lung physiology, cell motility, and inflammatory
reactions. RAGE and some of its ligands (HMGB1, S100A8/S100A9, and amyloid β-peptide) bind to
proteoglycans on the cell surface and these interactions regulate the ligand binding and signaling of
the receptor [1,2].
RAGE homodimerisation and oligomerisation occurs in cells [3]. Homophilic interactions of
RAGE in living cells is demonstrated with fluorescence resonance energy transfer and bioluminescence
resonance energy transfer methods [4,5]. Formation of RAGE homodimers and oligomers in solution
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is shown using various biochemical assays including cross-linking, nuclear magnetic resonance,
and X-ray crystallography methods [6,7].
Homodimerization and oligomerisation of RAGE can be regulated by receptor ligand binding.
In solution, heparin enhances dimer formation of soluble RAGE. Cleavage of heparan sulphate
chains on the cell surface inhibits RAGE signaling, suggesting that RAGE forms complexes with
proteoglycans [2]. In addition, homophilic interactions of RAGE can be regulated by S100 protein and
advanced glycation end product bovine serum albumin (AGE-BSA) ligands. Ligand induced receptor
dimerisation and oligomerisation is required for strong RAGE signaling [6,7].
α-D-Glucopyranosiduronic (glycyrrhizin) is a triterpenoid saponin derived from liquorice root.
It is a well-tolerated drug in humans and it has well-documented hepatoprotective effects in the
treatment of chronic hepatitis B and C infections [8–11]. Intravenous glycyrrhizin downregulates
serum aspartate aminotransferase and alanine transaminase levels and reduces the occurrence of
hepatocellular carcinoma. Further, glycyrrhizin has numerous other protective pharmacological
functions, like anti-ulcer and anti-allergic effects (reviewed in the literature [12,13]). Glycyrrhizin has
anti-viral effects in vitro and it dampens inflammatory reactions in various animal models [14–19].
Anti-inflammatory effects of glycyrrhizin are at least partly due to its ability to downregulate
proinflammatory cytokine expression and inhibit leukocyte diapedesis. Glycyrrhizin and heparin
have D-glucuronic acid units in their structure and they both are potent inhibitors of transendothelial
migration of leukocytes [20]. However, in heparin, D-glucuronic acid units are mostly C5-epimerised to
L-iduronic acid and are highly sulphated. Glycyrrhizin can be chemically sulphated, which potentiates
its anti-viral effects [21,22].
Both glycyrrhizin and heparin bind to HMGB1 and inhibit cell adhesion and migration to
HMGB1 [23–28]. HMGB1 mediates cell migration via both RAGE independent and dependent
mechanisms [29]. RAGE independent migration of cells can occur via HMGB1—stromal cell-derived
factor 1 (SDF-1) heterocomplex mediated pathway [28]. SDF-1 signals through C–X–C chemokine type
receptor 4 (CXCR4). In addition, SDF-1 binding to heparan sulphate proteoglycan (HSPG) type cell
surface receptors is a prerequisite to it promoting activity of tissue emigration of cells [30]. Further,
the importance of HMGB1 in cell migration in vivo was shown in the study by Oyama and others,
where decreased leukocyte diapedesis occurred in HMGB1 heterozygote mice [31]. It has been unclear
whether interactions of HMGB1 with HSPGs, which mediate cell adhesion and migration, can be
inhibited by glycyrrhizin.
Here, we have studied the targeting of RAGE and RAGE ligands by heparin and heparin-
related structures.
2. Materials and Methods
2.1. Materials
Recombinant HMGB1 was produced as described [32]. The extracellular coding regions of
human RAGE were cloned into the modified pRMHA3 vector containing the CD33 signal sequence
and human IgG Fc-part. Immunoglobulin fusion proteins were produced in Drosophila S2 cells
and purified using protein A-agarose chromatography as described [33,34]. Full length extracellular
human RAGE (sRAGE) contained amino acids 28–331; V1-domain amino acids 28–119; C1-domain
amino acids 120–231; C2-domain amino acids 232–331; delta V1 amino acids 120–331; delta C1 amino
acids 28–119 + 232–331; delta C2 amino acids 28–231. AGE-BSA was produced as described [35].
Recombinant HMGB1 A-box (amino acids 1–84) was produced as a glutathione S-transferase (GST)
fusion protein and purified using the same method as described for deltaC-HMGB1 purification [35].
Amyloid β peptide 1–42 was from American Peptide (Sunnyvale, CA, USA). K5 carbohydrates,
chondroitin sulphate, and dermatan sulphate were from Iduron (Manchester, United Kingdom).
Composition of K5 carbohydrates is described in the literature [36]. Glycyrrhizin (Sigma-Aldrich,
St. Louis, MO, USA) and glucose stock solutions (0.1–0.25 M) were made in 1% ethanol, pH 7.5 [37].
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Salt concentrations in glycyrrhizin and glucose stocks and in buffer controls were equalized. For PC3
adhesion studies, glycyrrhizin or glucose were dissolved in a NaOH solution as described [38].
Heparin was from Sigma-Aldrich.
2.2. Bead Aggregation Assay
Protein A coated bead aggregation mediated by recombinant Ig-fusion proteins was studied as
described [33]. In brief, monomeric fluorescent protein A coated beads were incubated with 10 µg/mL
of different sRAGE–Ig forms and aggregation was monitored using fluorescence microscopy (Olympus,
Tokyo, Japan). Pictures were taken after 60 min bead aggregation. The extent of bead aggregation
is represented by the index Nt/N0. Nt and N0 are the total number of particles at incubation times
t and 0, respectively.
2.3. Live-Cell Protein-Fragment Complementation Assay (PCA)
Full-length RAGE was cloned to plasmids containing complementary fragments of humanized
Gaussia (hGLuc) luciferase and livecell protein-fragment complementation assay was done as
described [39]. In brief, white-walled 96-well plates (Perkin Elmer, Waltham, MA, USA) were coated
with poly-L-lysine (Sigma), and 10,000 cells per well were seeded. Transfection of the phGLuc–RAGE
plasmids (100 ng of DNA per well) was performed after 24 h, while detection of PCA signal was
measured 48 h post-transfection. Culture media was changed 30 min before measurements to serum
and phenol red-free Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA, USA).
Luminescence was measured with Victor3 plate reader (Perkin Elmer) following injection of native
coelenterazine, the substrate for the GLuc (NanoLight Technology, Pinetop, AZ, USA). At least
four replicate wells per condition were analyzed and a minimum of three independent experiments
were performed.
2.4. Binding of Amyloid Beta 1–42 Peptide to RAGE
Ig-fusion protein of sRAGE in a concentration of 5 mg/mL was bound to protein A (1 mg/mL,
Sigma-Aldrich, St. Louis, MO, USA) coated wells (Maxisorb ELISA plates, Sigma-Aldrich). Unbound
proteins were washed away, and the wells were blocked with BSA (Sigma-Aldrich). Biotinylated
amyloid β 1–42 peptide (20 nM, American Peptide, Sunnyvale, CA, USA) or biotinylated HMGB1
(20 nM) were bound to the wells in the presence or absence of inhibitors, and unbound ligands were
washed away. Bound biotinylated ligands were detected with horse radish peroxidase conjugated
streptavidin (Sigma-Aldrich) and peroxidase substrate (Sigma-Aldrich). The color was developed
using o-phenylenediamine dihydrochloride peroxidase substrate (Sigma-Aldrich). Absorbance at
490 nm was measured.
2.5. RAGE Binding to AGE-BSA
Plastic Maxisorb microwells (Sigma-Aldrich) were coated with 20 µg/mL of AGE-BSA [35] and
blocked with BSA. sRAGE–Ig protein (0.1 µg/mL) was incubated in wells in the presence of various
amounts of glycyrrhizin. Bound proteins were quantified using horse radish peroxidase conjugated
goat anti-human IgG (Sigma-Aldrich). The color was developed with peroxidase substrate. Absorbance
was measured at 450 nm.
2.6. Cell Adhesion Studies
PC3 cell binding assay was carried out as described [40]. Briefly, Maxisorp (Sigma-Aldrich) wells
were coated with RAGE V1–Fc, collagen, laminin, or fibronectin [10 µg/mL in phosphate buffered
saline (PBS)]. Coated wells were washed with PBS, blocked with 0.5% BSA-PBS, and washed once
with PBS. Ten microliters of Iscoves’s Modified Dulbecco’s Media (IMDM, Invitrogen)–0.5% BSA
containing 11× concentration of possible inhibitors was added to wells, and 1 × 105 PC3 cells in 100 µL
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of IMDM–0.5% BSA was added to wells. Cells were adhered for 30 min at 37 ◦C and unbound cells
were washed away with warm IMDM–0.5% BSA (6 times) and bound cells were quantitated with
intracellular acidic phosphatase assay [26]. EDTA, heparin, and glucose served as control inhibitors in
cell adhesion studies.
2.7. HMGB1 Binding to Heparin
Heparin–Sepharose (GE Healthcare, Chicago, IL, USA) affinity chromatography of HMGB1 was
carried out as previously described using PBS as a chromatography buffer [26]. HMGB1 was loaded to
the column in the presence of different concentrations of glycyrrhizin, the column was washed with
PBS, and bound protein was eluted with PBS containing 1.5 M NaCl. In some experiments, HMGB1 or
thrombin were loaded onto the column in PBS and eluted with increasing amounts of glycyrrhizin in
PBS. HMGB1 in elution fractions was detected with an anti-HMGB1 immunoblot [32], and thrombin
was detected in a dot blot assay using Coomassie blue staining. The optical density (OD) values of
bands or dots were measured as described [35].
The effect of glycyrrhizin on HMGB1 A-box binding to heparin–Sepharose was studied using
heparin–Sepharose precipitation assay. The A-box was diluted with PBS (4 µg/mL) and an equal
volume of 50% heparin–Sepharose slurry in PBS was added. Glycyrrhizin or glucose were at
concentrations of 0–3 mM. Samples were incubated in rotation at 4 ◦C for 1 h, heparin–Sepharose
was pelleted and washed with PBS. Bound protein was eluted with 30 µL of hot reducing SDS-PAGE
sample buffer, and samples were analyzed using an anti-HMGB1 (anti peptide III, [32]) Western
blotting assay. The OD values of A-box bands were measured.
Precipitation assays of full length HMGB1 protein. HMGB1 was diluted with PBS (25 µg/mL) and
divided to 100 µL aliquots, and various amounts of glycyrrhizin or glucose were added. One-hundred
microliters of 50% heparin–Sepharose slurry in PBS was added to aliquots, and the samples were
incubated in rotation at 4 ◦C for 1 h. Heparin–Sepharose was washed once with PBS, and bound
proteins were eluted with 30 µL of hot reducing SDS-PAGE sample buffer. The samples were run
on SDS-PAGE and the gels were stained with Coomassie blue. The OD values of HMGB1 bands
were measured.
2.8. Data Analyses
Analyses were performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA,
USA), GraphPad Prism Software 4.0 (GraphPad Software Inc., La Jolla, CA, USA), and PSI-Plot V 7.0
(Poly Software International, Pearl River, NY, USA). Student’s t-test was used to compare group means.
p-values < 0.05 were considered as significant.
3. Results and Discussion
3.1. Nature of Homophilic RAGE Interactions
Homophilic interactions of RAGE are mediated by multiple mechanisms involving both extra
cellular and cytoplasmic domains [2–7]. Wei et al. have described non-covalent homophilic interactions
occur between V1-domains and dimerization by covalent homophilic bonding via interchain disulphide
bridge between C2-domains [3]. In addition, homophilic binding of soluble recombinant RAGE
protein have been shown to require high concentrations of protein and the presence of divalent metal
ions [41,42]. Here, we studied whether the homophilic interactions of recombinant sRAGE occur
in low protein concentrations using bead aggregation assay. Furthermore, we studied whether the
homophilic interactions of full length RAGE on a living cell surface can be inhibited by heparin.
Recombinant sRAGE–Ig protein and Ig-fragments bearing RAGE domains used in this study are
dimeric proteins. sRAGE–Ig and V1–Ig induced bead aggregation in protein-A coated bead suspension,
suggesting that dimeric RAGE is able to form oligomeric structures in low concentrations (10 µg/mL)
and in the absence of other exogenous ligands. The V1-domain was necessary and sufficient for
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observed oligomerisation. However, the lack of C2-domain in recombinant protein resulted in a






Figure 1. Bead aggregation assay of the receptor for advanced glycation end products (RAGE) 
homophilic binding. (A) Monomeric fluorescent protein A-coated beads were incubated with low 
concentration (10 μg/mL) of different Ig-tagged recombinant full length extracellular human RAGE 
(sRAGE) domains and aggregation was monitored using fluorescence microscopy. The images are 
taken after 60 min of bead aggregation. (B) Kinetics of bead aggregation. Nt and N0 are the total 
number of particles at incubation times t and 0, respectively. The extent of bead aggregation is 
represented by the index Nt/N0. Closed circle curve represents full-length sRAGE–Ig fusion protein, 
close triangle curve represents sRAGE–Ig fusion protein lacking V1-domain, open circle curve 
represents sRAGE–Ig fusion protein lacking C1-domain, cross curve represents sRAGE–Ig fusion 
protein lacking C2-domain, and close square curve represents Fc control protein coated beads. 
Whereas V1-domain was necessary and sufficient for homophilic binding of RAGE, the existence of 
the C2-domain in recombinant sRAGE-fragment was required for maximal homophilic binding of 
RAGE forms bearing the V1- and C2-domains. N ≥ 3; error bars represent ±SD. 
Figure 1. Bead aggregation assay of the receptor for advanced glycation end products (RAGE)
homophilic binding. (A) Monomeric fluorescent protein A-coated beads were incubated with low
concentration (10 µg/mL) of different Ig-tagged recombinant full length extracellular human RAGE
(sRAGE) domains and aggregation was monitored using fluorescence microscopy. The images are taken
after 60 min of bead aggregation. (B) Kin tics of bead aggregation. Nt a d N0 are the total umber of
particles at incubation times t and 0, respectively. The extent of bead aggregation is represented by
the index Nt/N0. Closed circle curve represents full-length sRAGE–Ig fusion protein, close triangle
curve represents sRAGE–Ig fusion protein lacking V1-domain, open circle curve represents sRAGE–Ig
fusion protein lacking C1-domain, cross curve represents sRAGE–Ig fusion protein lacking C2-domain,
and close square curve represents Fc control protein coated beads. Whereas V1-domain was necessary
and sufficient for homop ilic binding of RAGE, the existence of the C2-domain in recombinant
sRAGE-fragment was required for maximal homophilic binding of RAGE forms bearing the V1-
and C2-domains. N ≥ 3; error bars represent ±SD.
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Next, we studied the homophilic interactions of RAGE in living cells using a protein-fragment
complementation assay (PCA). In this assay, cells are transfected with full-length RAGE–cytoplasmic
Gaussia luciferase-fragment chimeras that become chemiluminescent when dimerised. Amyloid
precursor protein (APP) that forms homodimers served as a positive control (Figure 2A).
RAGE self-association occurred in living cells without any exogenous macromolecular ligands.
Self-association was partially inhibited by heparin (Figure 2B). Our results indicate that the soluble
dimeric ectodomain of RAGE, at low protein concentration and in the absence of exogenous ligands,
can form oligomers. Further, to our knowledge, this is the first time that it has been shown that RAGE
self-association in the living cells can be inhibited by heparin. As heparin does not penetrate through
the plasma membrane, the inhibition most probably occurs at the cell surface. Xu et al. have shown
that sRAGE dimerization is enhanced by heparin and dimerization at the cell surface is inhibited by
heparanase treatment [2]. Our results suggest that soluble heparin may interfere with cell surface
RAGE–heparan sulphate interactions that lead to dissociation of RAGE homodimer (Figure 3A).
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association was measured with luciferase activity. hDLuc fragment chimeras of APP served as a 
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Figure 2. Homophilic interacti of RAGE on the living cell surface are inhibited by heparin. (A) Cells
were transfected with full length RAGE–cytoplasmic hGLuc fragment chimeras. RAGE self-association
was measured with luciferase activity. hDLuc fragment chimeras of APP served as a positive control of
homodimerization. (B) RAGE self-association was partially inhibited by heparin. N = 3–4; error bars
represent ±SD. * = p < 0.05 when compared with untreated control. hGLuc = humanized Gaussia
luciferase, RLU = relative light unit, PCA = protein-fragment complementation assay, APP = amyloid β.
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Figure 3. Schematic picture showing RAGE and HMGB1 antagonists used in this study. (A) A
schematic picture showing RAGE extracellular V1-domain mediated interactions that were inhibited
by glycyrrhizin, sulphated K5 oligosaccharides, and heparin in this study. (B) A schematic picture
showing the predicted extracellular sulphated glycosaminoglycan binding of HMGB1 and inhibition
of binding and RAGE signaling by glycyrrhizin.
3.2. Sulphated K5 Polysaccharides I hibit RAGE Binding to Amyloi β-Peptide and HMGB1
Heparin that has a high content of sulphated L-iduronic acid units binds to RAGE and
inhibits RAGE–ligand binding and dimerization (Figure 2B and [1]). Epimerization of carbon C5
of D-glucuronic acid to create L-iduronic acid is not required for RAGE inhibition by sulphated
oligo acc ri es [43]. Capsul polysaccharide K5 derived from E. coli contains N-acetylglucosamine
and g ucuronic acid structures [44]. Here, we studied wheth r semi-synthetic non-epimerized
sulphated K5 polysaccharides inhibit RAGE–ligand binding. O- and N-sulphated K5 oligosaccharides
were able to inhibit RAGE binding to amyloid β-peptide and HMGB1 (Table 1) at similar concentrations
that have previously been shown for heparin [1,45]. The minimum size of oligosaccharides required for
strong inhibition was 3100–5800 Da. Sulphated disaccharides derived from chondroitin and dermatan
sulphates did not inhibit RAGE–ligand binding (data not shown). These results are in line with the
results from previous studies wh re the polymeric structure of sulphated carbohydrates was shown to
be essential for inhibition of RAGE–ligand binding and RAGE dimerization [1,2]. Our results indicate
that E. coli derived K5 polysaccharides can be used to design new RAGE targeting drug molecules
(Figure 3A).
Table 1. Sulphated K5 polysaccharides inhibit receptor for advanced glycation end products
(RAGE)–ligand binding. Binding of soluble biotinylated ligands to full length extracellular human
RAGE (sRAGE) coated plastic microwells was analysed as described in materials and methods.
Representative IC50 values are shown. NS = N-sulphated, OS = O-sulphated, OS(H) = highly
O-sulphated, 3100 = size of 3100 Da, 5800 = size of 5800 Da. ND = not determined.
Polusaccharide Amyloid β-Peptide HMGB1
K5 6837 µg/mL ND
K5 NS 34.7 µg/mL ND
K5 OS (H) 0.9 µg/mL ND
K5 NS, OS (H) 1.5 µg/mL 1.0 µg/mL
K5 NS, OS (H) 3100 21.3 µg/mL 0.9 µg/mL
K5 NS, OS (H) 5800 1.6 µg/mL 0.9 µg/mL
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3.3. Glycyrrhizin and Heparin Inhibit AGE–RAGE -Interactions
Glycyrrhizin has two non-sulphated D-glucuronic acids in its structure and it inhibits RAGE
binding to HMGB1 [46]. The inhibition is mainly due to binding of glycyrrhizin to HMGB1. However,
glycyrrhizin shows minimal binding on RAGE. In addition, glycyrrhizin interferes HMGB1 binding
to CXCR4, Toll-like receptor 2, and Toll-like receptor 4 [25,28,38]. Glycyrrhizin might be a potential
molecule for RAGE targeting drug development because it can be easily modified [21,22]. Here,
we tested whether glycyrrhizin affects homophilic interactions of RAGE in cell culture conditions
using the PCA assay. Surprisingly, glycyrrhizin inhibited full-length luciferase activity in cells, that is,
it was incompatible with the assay, thereby preventing further studies with glycyrrhizin in the PCA
assay (data not shown).
AGE-BSA binding to RAGE induces receptor dimerization and signaling [47]. Here, we studied
whether glycyrrhizin interferes with binding of RAGE to AGE-BSA. In a microwell binding assay,
300 µM glycyrrhizin inhibited RAGE binding to AGE-BSA coated microwells (Figure 4). The effect
of glycyrrhizin on RAGE–AGE interactions was also tested in cell adhesion assay. PC3 cells express
endogenously synthetized AGEs on their surface, which mediate cell binding to RAGE [40,48,49].
PC3 cells adhered to RAGE V1-domain, but not to C1- or C2-domains ([40]; data not shown).
Glycyrrhizin at 1 mM concentration inhibited PC3 cell binding to RAGE V1-domain, but not to
the control proteins fibronectin, laminin, or collagen. Furthermore, heparin inhibited cell binding to
both RAGE V1-domain and fibronectin, but not to laminin and collagen. In contrast, EDTA inhibited
cell binding to fibronectin, laminin, and collagen, but not to RAGE V1-domain (Figure 5). The finding
that the cell binding to RAGE occurs independently of divalent cations excludes the role of Mac-1
integrin in the binding [45]. Our results indicate that AGE binding to RAGE can be inhibited by
glycyrrhizin and heparin (Figure 3A).
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site but has a heparin-binding site, inhibits cell migration [54–57]. This suggests that HMGB1 binding
to HSPGs might be necessary to RAGE–HMGB1 complex signaling. Here, we studied the effect
of glycyrrhizin on HMGB1 heparin binding. First, we tested whether A-box binds to heparin in
a similar manner to the full-length HMGB1. The A-box bound to a heparin–Sepharose in column
chromatography and was eluted with the same NaCl concentration (~0.7 M) as full-length HMGB1
(data not shown). This suggests that the A-box lacking heparin binding cationic amino acid residues in
a linker sequence is still able to bind to heparin.
Next, we tested whether glycyrrhizin can inhibit heparin binding in heparin–Sepharose
chromatography. The excess of glycyrrhizin prevented HMGB1 binding to the chromatography column
(Figure 6A). Further, a heparin–Sepharose column bound HMGB1 was eluted with a glycyrrhizin
gradient at the same concentration of glycyrrhizin as the control protein thrombin ([58]; data not
shown). Next, we studied the effect of glycyrrhizin on heparin binding of full-length HMGB1 and
A-box using a heparin–Sepharose precipitation assay. Glycyrrhizin inhibited binding of both the
full-length HMGB1 and the A-box (Figure 6B,C). These results indicate that the A-box and the full
length HMGB1 bind to heparin in a similar manner, and that their binding to heparin is inhibited by
millimolar concentrations of glycyrrhizin. It is tempting to speculate that glycyrrhizin might inhibit
RAGE signaling via interfering HMGB1–heparan sulphate interactions (Figure 3B).
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